このエントリーをはてなブックマークに追加


ID 64248
フルテキストURL
著者
Matsumoto, Naomi Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID Kaken ID researchmap
Hagiya, Hideharu Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID researchmap
Nakayama, Masanori Office of Innovative Medicine, Organization for Research Strategy and Development, Okayama University
Furukawa, Masanori Clinical Laboratory, Okayama University Hospital
Mitsuhashi, Toshiharu Center for Innovative Clinical Medicine, Okayama University Hospital Kaken ID researchmap
Takao, Soshi Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Otsuka, Fumio Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Yorifuji, Takashi Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
抄録
Background: To mitigate the COVID-19 pandemic, many countries have recommended the use of booster vac-cinations. The relationship between the degree of adverse vaccine reactions and elevated antibody titers is of interest; however, no studies have investigated the temporal changes in antibody titers based on repeated measurements after a third dose of the BNT162b2 vaccine.
Methods: This prospective longitudinal cohort study was conducted with 62 healthcare workers who received a third dose of the BNT162b2 at Okayama University Hospital, Japan. Venous blood draw and fingertip whole blood test sample collection were conducted at the early (3-13 days) and 1-month time points; only FWT sample collection was conducted at the 2-month time point. Information on adverse reactions within 1 week after vaccination was also obtained. The association between fever of 37.5 degrees C or higher and antibody titers after the third dose of BNT162b2 was examined using a mixed-effects model and Poisson regression with robust variance.
Results: A trend toward higher antibody titers in the early period after vaccination was observed in the febrile individuals, but the differences were not significant at 1 and 2 months post-vaccination (the partial regression coefficient for fever was 8094.3 [-1910.2, 18,098.8] at 1 month after vaccination, and 1764.1 [-4133.9, 7662.1] at 2 months after vaccination in the adjusted models).
Conclusion: The findings suggest that the presence of fever after the third vaccine does not predict a sustained elevation in serum antibody titers.
キーワード
SARS-CoV-2
Vaccine
Antibody
Reactogenicity
Adverse reaction
Mixed-effects model
備考
© 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. This manuscript version is made available under the CC-BY-NC-ND 4.0 License. http://creativecommons.org/licenses/by-nc-nd/4.0/. This is the accepted manuscript version. The formal published version is available at [https://doi.org/10.1016/j.jiac.2022.09.012] .
This full-text file will be available in Nov. 2023.
発行日
2022-11-12
出版物タイトル
Journal of Infection and Chemotherapy
29巻
1号
出版者
Elsevier BV
開始ページ
39
終了ページ
42
ISSN
1341-321X
NCID
AA11057978
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
論文のバージョン
author
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1016/j.jiac.2022.09.012
ライセンス
http://creativecommons.org/licenses/by-nc-nd/4.0/
助成機関名
Okayama Prefecture
助成番号
7402000035